Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Watchlist | Portfolio | Dashboard

Contact

quotes
- Price Overview
- Performance Report
charts
- Interactive Chart
- Snapshot Chart
technicals
options
options strategies
company
analysts
- Earnings Estimates
- Analyst Ratings
financials

Relmada Therapeutics Inc (RLMD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] by (Cboe BZX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]

News & Headlines for [[ item.sessionDateDisplayLong ]]

Notes

Alerts

Watch

Help

Relmada Therapeutics Announces Discontinuation of Reliance II and Relight Phase 3 Studies, Explores Strategic Alternatives Quiver Quantitative, Inc. - Mon Dec 9, 4:50PM CST

Relmada Therapeutics discontinues Phase 3 studies and explores strategic alternatives to enhance shareholder value.Quiver AI SummaryRelmada Therapeutics, Inc., a biotechnology company focused on central...

Relmada Therapeutics Initiates Phase 1 Study of REL-P11, a Low-Dose Psilocybin Formulation for Metabolic Disease Quiver Quantitative, Inc. - Thu Nov 14, 5:04PM CST

Relmada initiates Phase 1 study for REL-P11, a psilocybin formulation for metabolic disorders, with Phase 2a planned for 2025.Quiver AI SummaryRelmada Therapeutics has announced the initiation of dosing...

Healthcare - COVID-19 vaccines by HakanGERMAN via Pixabay

2 Breakout Biotech Stocks With CEO Insider Buying Barchart - Tue Sep 17, 2:09PM CDT

These two breakout stocks are on a stellar run higher on the charts, but should investors follow executives into the shares?

Relmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver Meeting® 2023 PR Newswire - Wed Oct 11, 2023